Patent ID: 11884723
Assignee: OSE IMMUNOTHERAPEUTICS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 0:
1. A method of treating a cancer in a subject that expresses SIRPa v1, the method comprising administering to a subject a therapeutic amount of an anti-human SIRPa antibody, antigen-binding fragment thereof, or modified antibody thereof, which comprises:
a) a heavy chain variable domain comprising HCDR1, HCDR2 and HCDR3, wherein: HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9, HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11, HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; and
b) a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 17, wherein the antibody, antigen-binding fragment thereof, or modified antibody thereof, enhances cross presentation of an antigen expressed in said disease and is involved in eliciting a T cell response suitable for the treatment of said disease.